Xbrane Biopharma AB (publ) logo

Xbrane Biopharma AB (publ)

SSE:XBRANE.ST

Overview | Financials
Company Name Xbrane Biopharma AB (publ)
Symbol XBRANE.ST
Currency SEK
Price 2.085
Market Cap 61,989,344
Dividend Yield 0%
52-week-range 1.19 - 104.2
Industry Biotechnology
Sector Healthcare
CEO Mr. Siavash Bashiri
Website https://www.xbrane.com

An error occurred while fetching data.

About Xbrane Biopharma AB (publ)

Xbrane Biopharma AB (publ), a biotechnology company, develops, manufactures, and sells biosimilars. The company is developing Xlucane, a ranibizumab biosimilar that is in Phase III clinical trials used for the treatment of wet age-related macular degeneration, diabetic macular edema, diabetic related retinopathy, and retinal vein occlusion. Its pre-clinical phase products

Related Stocks

Mentice AB (publ) logo

Mentice AB (publ)

MNTC.ST

34.4 SEK

Doxa AB (publ) logo

Doxa AB (publ)

DOXA.ST

3.2 SEK

IRLAB Therapeutics AB (publ) logo

IRLAB Therapeutics AB (publ)

IRLAB-A.ST

14.45 SEK

Intervacc AB (publ) logo

Intervacc AB (publ)

IVACC.ST

3.735 SEK

Vicore Pharma Holding AB (publ) logo

Vicore Pharma Holding AB (publ)

VICO.ST

14.38 SEK

RaySearch Laboratories AB (publ) logo

RaySearch Laboratories AB (publ)

RAY-B.ST

92.2 SEK

Elos Medtech AB (publ) logo

Elos Medtech AB (publ)

ELOS-B.ST

203 SEK

Isofol Medical AB (publ) logo

Isofol Medical AB (publ)

ISOFOL.ST

0.616 SEK

Humana AB (publ) logo

Humana AB (publ)

HUM.ST

27 SEK

Q-linea AB (publ) logo

Q-linea AB (publ)

QLINEA.ST

2.49 SEK

Financials

Numbers are in millions USD

Numbers are in millions USD